Imaging Technology News

QT Imaging Advances U.S. Commercial Strategy to Accelerate Adoption of Breast Acoustic CT Scanner

tim.hodson — Tue, 04 Aug 2026 20:08:40 +0000

tim.hodson Tue, 08/04/2026 - 15:08

Aug. 3, 2026 — QT Imaging Holdings, is advancing the direct U.S. commercial strategy for its Breast Acoustic CT Scanner with the appointment of Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West. Both executives joined QT Imaging in July 2026 and report to Satrajit Misra, the company’s Chief Commercial Officer.

“Building a direct U.S. commercial organization is an important step in QT Imaging’s evolution into a scalable precision imaging platform,” said Misra. “Jason and Dave bring tremendous experience in breast imaging and surgical oncology, established relationships across major healthcare systems, and proven records of introducing innovative medical technologies into complex clinical care environments.

“Working directly with breast imaging centers, clinicians and enterprise health systems will provide a better understanding of their clinical, operational and economic priorities, support evidence generation and physician education, and develop a more direct pathway for adoption of our technology,” he added. “We value our relationship with NXC Imaging and will continue to work collaboratively as we build the internal capabilities to support our next phase of growth.”

These hires support the company’s evolution from a distributor-led sales model toward an integrated commercial model that enhances QT Imaging’s gross margin, direct ownership of customer engagement, strategic account development, clinical education and market development. QT Imaging will continue to work collaboratively with NXC Imaging, Inc., a wholly owned subsidiary of Canon Medical Systems USA, Inc., under the existing distribution arrangement.

QT Imaging’s commercial team will focus on developing relationships with leading medical centers and clinical stakeholders, assessing customer needs and establishing the infrastructure to support the Company’s longer-term U.S. commercialization strategy. Based on initial success and market feedback, QT Imaging may selectively add further commercial resources in 2027.

By combining the reach and resources of its established distribution relationship with a focused direct commercial organization, QT Imaging aims to strengthen customer relationships, support broader clinical adoption, expand evidence-supported applications, and build a scalable platform for sustainable long-term growth.

Breast Imaging Industry Veterans

Dyer brings two decades of commercial leadership experience across breast imaging, breast cancer diagnostics, surgical oncology and medical devices. Before QT Imaging, he served as Vice President of Sales and Service at Clarix Imaging, where he helped build the company’s initial commercial organization following FDA clearance of its 3D breast specimen CT imaging system and supported significant commercial growth.

Reinhart brings more than 35 years of experience in breast imaging, breast cancer diagnostics, surgical oncology, ultrasound, and medical device commercialization. He has held senior commercial roles at Merit Medical Oncology, Clarix Imaging, SonoCiné, Bioptics/Faxitron and Siemens Medical Systems. Throughout his career, Mr. Reinhart has worked alongside breast radiologists, surgeons and healthcare administrators to introduce innovative technologies across major health systems.

For additional information go to www.qtimaging.com.

Tuesday, August 4, 2026 - 15:08

When Patients Read Radiology Reports First

tim.hodson — Mon, 03 Aug 2026 19:46:53 +0000

tim.hodson Mon, 08/03/2026 - 14:46

GE HealthCare Expands Breast Imaging Portfolio

tim.hodson — Mon, 03 Aug 2026 17:06:08 +0000

tim.hodson Mon, 08/03/2026 - 12:06

Aug. 3, 2026 — GE HealthCare has launched Invenia ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue, a redesigned enterprise viewer that recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, expanding its breast imaging portfolio with solutions designed to support supplemental screening for women with dense breasts and provide more flexible enterprise-wide exam review. Together, these new solutions aim to help breast imaging programs standardize 3D ultrasound acquisition, support remote reading, and simplify deployment across multi-site networks.

Studies conducted in the U.S. and Europe show 40% of women have dense breasts¹, these women have a four to six times higher risk of developing breast cancer.² Dense breasts can make cancers harder to detect on mammography, and may delay diagnosis.^3,4,5 Research has shown that mammography may miss one-third of cancers in dense breasts, underscoring the need for supplemental screening options for these patients.⁶ According to results from the Breast Screening: Risk Adaptive Imaging for Density study, ABUS demonstrated higher acceptance and a more positive patient experience compared to other contrast-enhanced techniques.⁷

Supporting Breast Imaging Networks

“Invenia ABUS Prime builds on our commitment to advancing supplemental breast screening for women with dense breasts,” said Karley Yoder, CEO, Ultrasound Solutions, Advanced Imaging Solutions, GE HealthCare. “As breast imaging networks look to scale across sites, Invenia ABUS Prime can help deliver streamlined workflows, reproducible imaging, with features designed to support both patient comfort and clinician efficiency.”

When used alongside mammography, Invenia ABUS Prime supports earlier cancer detection.⁸ Across growing breast imaging networks, the system helps support standardized exams, more efficient workflows and operational consistency, particularly in multi-site imaging environments.

Invenia ABUS Prime features:

cSound Imageformer with AI-enabled tools including Scan Quality Assessment and Auto Nipple Detection — powered by Verisound AI — developed to help deliver consistent, reproducible, high-quality scans and greater clinical confidence
A Fast Scan tool that increases scan speed by up to 40%, along with a new-generation Reverse Curve transducer and selectable compression levels intended to enhance patient comfort and offer a more personalized patient experience⁹
AI-supported reading powered by QVCAD is designed to streamline review.¹⁰ AI Assistant powered by QVCAD has demonstrated a 33% reduction in reading time¹¹ and up to 93% sensitivity for lesion detection¹²

ABUS StreamVue is a zero-footprint, browser-based reading solution built to standardize ABUS exam review with remote access and adaptable licensing intended to simplify installation, maintenance and growth for enterprise imaging environments. Candelis, Inc. is collaborating with GE HealthCare to deliver ABUS StreamVue technology in combination with Invenia ABUS. Together with Invenia ABUS Prime, this technology aims to facilitate faster reads, remote reading and easier comparisons across sites, while assisting IT teams in managing ultrasound systems more simply across the enterprise.

“ABUS StreamVue extends the value of our ABUS platform with a flexible reading experience for enterprise imaging environments,” said Russ Behler, Global Product Director, LOGIQ Ultrasound, GE HealthCare. “This solution supports remote review, more standardized presentation and simpler deployment across care settings.”

Among the first U.S. installations of Invenia ABUS Prime is in Los Angeles at BeSound, which offers a modern breast imaging experience to expand access to supplemental breast cancer screening. BeSound is also planning a mobile screening unit to bring imaging services closer to patients.

“At BeSound, our mission is to make supplemental breast screening more accessible and more convenient for the women who need it,” said Bailey Renger, Founder and CEO, BeSound. “With Invenia ABUS Prime, we hope to expand access to advanced breast imaging in a way that is patient-centered and meets women where they are.”

Invenia ABUS Prime is U.S. FDA Premarket approved and CE Marked. Availability is subject to local regulatory approvals and may vary by country. ABUS StreamVue is U.S. FDA 510(k) cleared and CE Marked.

For more information on Invenia ABUS Prime and ABUS StreamVue, visit www.gehealthcare.com/en/products/ultrasound/breast-ultrasound/invenia-abus.

*Powered by Candelis.

References

Pisano et al. NEJM 2005; 353: 1773.
Boyd NF et al. NEJM 2007; 356: 227-36.
Engmann NJ, et al, JAMA Oncol. 2017;3(9):1228-1236
Mandelson et al. J Natl Cancer Inst 2000; 92:1081-1087.
Tagliafico, Massimo Calabrese et al, Journal of Clinical Oncology 2016 34:16, 1882-188.
Mandelson et al. J Natl Cancer Inst 2000; 92:1081-1087.
Allajbeu et.al., Acceptance, experience, and feedback for supplemental screening in dense breasts among women participating in the BRAID trial. Insights into Imaging, (2026) 17:14 https://doi.org/10.1186/s13244-025-02170-8.
The Lancet; May 2025; www.thelancet.com/journals/lancet/article/PIIS0140‑6736(25)00582‑3/fulltext.
Compared to Invenia ABUS 2.0.
QVCAD is a trademark of QView Medical, Inc.
Performance and Reading Time of Automated Breast US with or without Computer-Aided Detection. https://pubs.rsna.org/doi/10.1148/radiol.2019181816.
Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women with Dense Breast Tissue (Yulei Jiang) Read more: www.ajronline.org/doi/10.2214/AJR.18.19516.

Monday, August 3, 2026 - 12:06

New Guideline Addresses Musculoskeletal Disorders for Cardiac Sonographers

tim.hodson — Mon, 03 Aug 2026 17:00:00 +0000

tim.hodson Mon, 08/03/2026 - 12:00

August 3, 2026 — Despite improvements in technology and awareness, work-related musculoskeletal disorders (WRMSDs) remain one of the greatest threats to the longevity of a cardiac sonographer’s career. A new guideline published by the American Society of Echocardiography (ASE) provides evidence-based recommendations to reduce the risk of WRMSDs and strengthen the cardiovascular imaging workforce.

WRMSD injuries not only affect the individual sonographer, but also patient access to care, workforce retention and the long-term sustainability of echocardiography. “Guidelines for the Prevention of Work-Related Musculoskeletal Disorders for Cardiac Sonographers: Recommendations from the American Society of Echocardiography” outlines recommendations for education, injury prevention, and workplace culture to prioritize safety and sustainability. It includes guidance on ergonomic equipment standards, safe scanning techniques, environmental design, scheduling strategies, early symptom recognition and the integration of emerging technologies, such as artificial intelligence and wearable feedback tools.

“For too long, musculoskeletal injury has been viewed as an expected part of being a cardiac sonographer,” said Guideline Chair Ashlee Davis, chief technologist at Duke University Hospital and manager and technical director for the institution’s Cardiac Diagnostic Unit. “This guideline challenges that mindset by demonstrating that many of these injuries are preventable through thoughtful design, education and organizational commitment.”

Davis said one of the guideline’s greatest strengths is its emphasis on injury prevention as a shared responsibility.

“While individual scanning techniques and ergonomics are important, meaningful change also requires support from employers, healthcare leaders, equipment manufacturers, educators and professional societies,” she said.

Guideline Co-Chair Allyson Boyle, director of echocardiography at Atrium Health, added that the recommendations were developed by experts committed to improving cardiac sonographers’ long-term health and diagnostic capabilities.

“We hope the guideline not only raises awareness of the prevalence and impact of WRMSDs but also empowers sonographers to prioritize their health and inspires healthcare organizations to take meaningful action,” Boyle said. “Investing in sonographer safety is an investment in workforce sustainability, quality patient care, and the future of the profession.”

As echocardiography laboratories face growing patient demand amid staff shortages, WRMSDs threaten both performance and retention. ASE President Dr. Cynthia Taub, Edward C. Reifenstein Endowed Professor and chair of medicine at the State University of New York Upstate Medical University, said that the guideline reflects ASE’s commitment to protecting cardiac sonographers.

“Protecting the long-term health of cardiac sonographers is fundamental to the future of the cardiovascular imaging,” Taub said. “With this guideline, ASE is providing much needed advice to help healthcare organizations create safer, more sustainable workplaces and ensure continued access to high-quality patient care.

Acces to the Guideline

The complete guideline, along with all guidelines published by ASE, are available at ASEcho.org/Guidelines.

Monday, August 3, 2026 - 12:00

AI-Powered Breast Ultrasound Receives FDA Clearance

tim.hodson — Fri, 31 Jul 2026 16:55:29 +0000

tim.hodson Fri, 07/31/2026 - 11:55

July 30, 2026 — DeepHealth, Inc. has received FDA 510(k) clearance for DeepHealth Breast Ultrasound¹, an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging. DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry.

In addition to a multi-reader multi-case study involving 16 U.S. board-certified radiologists at select imaging centers and hospitals², RadNet has validated the effectiveness of DeepHealth Breast Ultrasound in live clinical settings under regulated research protocols. Now with FDA clearance, DeepHealth Breast Ultrasound is commercially available for sale to customers in the United States who can pursue reimbursement under an existing Category III CPT code for quantitative ultrasound tissue characterization³. By the end of this year, the solution will be implemented across RadNet’s network of centers, with an estimated more than 700,000 breast ultrasound studies annually that may be eligible for reimbursement.

Breast Ultrasound

“Breast ultrasound is an essential component of the breast care pathway, with approximately 40% of women undergoing the exam at some point in their lives⁴. It is a highly complex, operator-dependent examination, which can lead to significant variability in image acquisition, interpretation and reporting,” said Dr. Jason McKellop, Medical Director of Women’s Imaging for RadNet California. “With DeepHealth’s breast ultrasound solution, we can achieve greater standardization of workflows, improving consistency while saving time for patients, sonographers and radiologists. By streamlining the examination process, we can help reduce exam times, enhance efficiency and ultimately improve patient outcomes.”

DeepHealth Breast Ultrasound is designed to support more efficient and standardized ultrasound workflows through:

Automated lesion detection – Assists the interpreting physician to localize the presence or absence of suspicious soft-tissue lesionsin standard ultrasound breast images, with demonstrated greater than 98% accuracy in localizing breast lesions and improved sensitivity for breast cancer detection by 8%2
Automated lesion characterization – Analyzes images acquired by the sonographer to assist the interpreting physician in generating and characterizing the lesion shape, orientation, margin, echo pattern and posterior features, in line with ACR BI-RADS, reducing radiologist interpretation time by 37%2
Automated reporting – Generates a comprehensive radiology report of the key findings and impressions, helping radiologists move more efficiently from image review to final report while retaining control of the final assessment
Expedited sonographer workflow – Automatically extracts and organizes lesion measurements, characteristics and other relevant findings in a standardized format, reducing manual documentation for sonographers with the aim of reducing overall exam time

“No single imaging pathway addresses every woman’s needs. With the addition of Breast Ultrasound, we are proud to support women across a broader range of screening and diagnostic pathways, including those with dense breasts and others who may require supplemental imaging. Bringing together AI-powered capabilities across mammography and ultrasound helps clinicians respond to different imaging needs and deliver more comprehensive, personalized breast care,” said Niccolò Stefani, M.D., Business and Product Leader, Clinical AI at DeepHealth.

DeepHealth’s breast imaging platform⁵ — a modular, interoperable AI-powered portfolio addressing real-world clinical needs across breast cancer screening and diagnostic pathways — includes applications for cancer detection in both mammography and ultrasound, density assessment, breast arterial calcification assessment, image-based breast cancer risk prediction⁶ and mammography quality analytics, with viewing and reporting tools for improved operational efficiency.

References

Deephealth Breast Ultrasound is the commercial name for the See-Mode Augmented Reporting Tool, Breast (SMART-B) device, cleared by the FDA under 510(k) K260303. The clearance is held by See-Mode Technologies Pty Ltd, a DeepHealth company, which manufactures the device; it is distributed in the United States by DeepHealth, Inc.
Data on file. Based on data from MRMC study submitted to FDA for 510(k) clearance K260303.
Reimbursement depends on payer policy.
Based on change of regulations and gold-standard approach in breast cancer screening. U.S. Food and Drug Administration. Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide—Guidance for Industry and Food and Drug Administration Staff. Issued August 26, 2024, www.fda.gov/media/181152/download.
U.S. Food and Drug Administration. Understanding Breast Density. FDA Office of Women’s Health. www.fda.gov/consumers/womens-health-topics/understanding-breast-density
DeepHealth breast solutions comprise multiple applications, including Mammo Dx, Breast Density, Safeguard Review, Risk Assessment, BAC Assessment, Mammography Insight, Breast Ultrasound and workflow tools including DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Mammography Insights is manufactured by Aquila, Inc. and distributed by DeepHealth, Inc.
Not cleared for use in the U.S. Capability available in Europe.

Friday, July 31, 2026 - 11:55

Registration Now Open for RSNA 2026

tim.hodson — Fri, 31 Jul 2026 15:13:15 +0000

tim.hodson Fri, 07/31/2026 - 10:13

Registration for RSNA 2026 is now open.

The Radiological Society of North America's annual meeting will take place Nov. 29 to Dec. 3, at the McCormick Place in Chicago, Illinois.

The RSNA annual meeting is the world’s leading radiology forum; offering a robust research and education program, access to the latest medical imaging technologies and an array of opportunities for professional engagement and career advancement.

This year’s theme, "At the Center of Care," is highlighted in a dynamic plenary lineup and emphasizes the important role radiologists play in healthcare. Imaging professionals around the world continue to shape patient-centered care, using innovation, collaboration and imaging expertise to support earlier detection, more precise diagnosis and informed treatment decisions.

RSNA 2026 also boasts the ultimate radiology show floor for demonstrating the latest medical imaging ideas and innovations in CT, MRI, AI, 3D technology and more.

Exceptional social and networking experiences at RSNA 2026 will help attendees build connections across the global radiology community. Onsite resources and services are designed to make the meeting experience productive, comfortable and accessible.

Hotel reservations are available. Special discounted meeting rates have been negotiated at nearly 60 hotels.

More Information on RSNA 2026

Click here to learn more about the education program, technical exhibits, travel information and to register to attend.

Friday, July 31, 2026 - 10:13

Vanderbilt Health, Siemens Healthineers Partner to Deliver Advanced Technology, Elevate Patient Care

tim.hodson — Tue, 28 Jul 2026 18:57:51 +0000

tim.hodson Tue, 07/28/2026 - 13:57

July 27, 2026 — Vanderbilt Health and Siemens Healthineers have entered into a multi-year, $87 million Value Partnership¹ to modernize and standardize diagnostic imaging, radiation oncology and related workforce development programs across Vanderbilt Health’s hospitals in the Nashville area. The agreement establishes a strategic framework for performance innovation, technology planning, installation support and service operations, aligning strategy with clinical and operational goals. The relationship will streamline technology for select equipment purchases and upgrades while planned new ventures enhance operations.

“Our mission is to continually provide patients first access to the very latest advancements,” said Jane Freedman MD, deputy chief executive officer and chief health system officer for Vanderbilt Health. “Joining with Siemens Healthineers, a world leader in healthcare equipment, will help our health system remain on the cutting edge regarding imaging technology implementation while also offering access to their other innovations.”

Vanderbilt Health and Siemens Healthineers also will explore opportunities involving data infrastructure, AI-enabled technologies and workflow innovation in radiology and personalized medicine. These efforts are intended to support clinical teams, improve operational efficiency and develop care models for wider application.

Providing Advanced Technology

Under the agreement, Siemens Healthineers will provide advanced technology for magnetic resonance imaging, computed tomography, molecular imaging, interventional radiology and radiation oncology systems for Vanderbilt Health locations including University Hospital and Monroe Carell Jr. Children’s Hospital at Vanderbilt. The Value Partnership is intended to strengthen Vanderbilt Health’s patient-centered approach to personalized care delivery, enhance the patient experience and further efforts to improve health outcomes for communities across Middle Tennessee.

“Vanderbilt Health is known for its clinical excellence, research leadership and commitment to patient-centered care,” said John Kowal, president and head of the Americas at Siemens Healthineers. “We are proud to support them with advanced imaging and radiation oncology technology, operational expertise and a framework for innovation that can help improve care delivery today and anticipate the needs of tomorrow.”

Value Partnerships are long-term and comprehensive partnerships between Siemens Healthineers and healthcare providers, enabling them to create more value to better treat patients and reduce operational complexity.

Tuesday, July 28, 2026 - 13:57

New AI Model for Chest CT Exams Now Available from HOPPR

tim.hodson — Mon, 27 Jul 2026 21:44:42 +0000

tim.hodson Mon, 07/27/2026 - 16:44

July 23, 2026 — HOPPR has introduced HOPPR EF Chest CT Narrative Model, a foundation model that processes 3D chest CT volumes and generates narrative language describing image characteristics across pulmonary, mediastinal, cardiac, upper abdominal, osseous, and soft tissue regions. The model is now available through HOPPR Forward Deployed Services, giving development teams expert support across every stage from evaluation to integration.

The HOPPR EF Chest CT Narrative Model was trained on a large proprietary dataset of chest CT studies from multiple clinical sites across the United States. A deliberate emphasis was placed on ensuring serious but less common conditions, including aortic injury, pulmonary embolism, rib fractures, and pneumothorax, are well represented in training. This approach reflects HOPPR’s focus on building models that are useful across the realistic range of what clinicians encounter, not just the most routine cases.

“Chest CT is one of the most information-dense studies in radiology. Getting AI to work well across everything it captures — the lungs, the heart, the aorta — is a genuinely hard problem, and we are pleased with what this model can do,” said Khan Siddiqui, M.D., co-founder and CEO of HOPPR. “But the model is only part of what we are building. Our AI Foundry and Forward Deployed Services include secure infrastructure, curated data, and the clinical and technical expertise to help any organization move from a foundation model to a working application, regardless of where they are starting from. That is what makes this more than a model release.”

HOPPR Portfolio

With this release, HOPPR’s foundation model portfolio now spans three imaging modalities: chest X-ray, mammography and chest CT. The portfolio covers both AI-assisted classification and narrative-language-generation tasks. Models are available on the HOPPR AI Foundry alongside third-party models from NVIDIA, Google, Microsoft, Stanford AIMI, and others. The Foundry also provides access to curated datasets and traceable development workflows, giving partners the data infrastructure and governance foundations that are difficult and expensive to build independently in a regulated healthcare environment.

“Working with HOPPR’s Forward Deployed Services team has allowed us to evaluate the Chest CT Narrative Model against our own data without needing to build that capability internally,” said Kevin Kadakia, Chief Operating Officer at RadiologyOne. “The ability to adapt the model to our specific workflow and imaging environment is exactly what we were looking for in a foundation model partner.”

What distinguishes HOPPR is not just the models. Foundation models on the HOPPR AI Foundry are built on secure, HIPAA-ready infrastructure that is SOC 2 Type II and HITRUST e1 certified, and operates under a Quality Management System. Partners also have access to HOPPR Forward Deployed Services (FDS), a flexible engagement model that provides clinical workflow expertise, machine learning, fine-tuning, integration, and deployment support depending on what a team needs. Some partners need deep technical support to modify a model on their own data. Others need help navigating clinical workflow requirements or regulatory preparation. FDS meets them where they are, filling in the gaps that stand between a foundation model and a working application.

To get started with the HOPPR EF CT Chest Mammography Narrative Model, click here.

Monday, July 27, 2026 - 16:44

UW Health Kids Establishes First Pediatric Interventional Radiology Suite

tim.hodson — Thu, 23 Jul 2026 17:25:26 +0000

tim.hodson Thu, 07/23/2026 - 12:25

July 17, 2026 — In June, UW Health Kids began welcoming patients into a new state-of-the-art imaging suite dedicated to interventional radiology for pediatric patients at American Family Children’s Hospital in Madison, Wisconsin.

Interventional radiology is a medical subspecialty that uses medical imaging such as MRI, ultrasound, fluoroscopy and computed tomography, known as CT scans, to guide minimally invasive surgical procedures. These procedures are highly precise, less invasive and can enable faster recoveries, which is so important for young patients, according to Dr. Eric Monroe, pediatric interventional radiologist, UW Health Kids, and professor of radiology, University of Wisconsin School of Medicine and Public Health.

“Our care team supports all kinds of patients, from those with vascular disorders to those with cancer, performing a wide range of procedures and interventions such as placing catheters, performing biopsies and more,” he said. “This new space is going to enable us to perform all these vital services for so many more patients moving forward.”

The suite will serve patients in the hospital and will also be available for outpatient procedures. It features several advanced technologies that enable flexible use of the space, including an imaging C-shaped arm with an AI-supported guidance tool attached to the center of the room that allows the care team to move the imaging to and around the patient, making it supportive of all body types and improving comfort for the patient during the procedure. The system can also then be moved away from the patient before or after a procedure, making the space less confining or stressful for young patients, according to Monroe.

In addition, the suite features highly advanced technologies, including 3D imaging solutions and advanced navigational tools.

The image-guiding solution in the suite, called Allia Moveo, was developed by GE HealthCare, which has a long-standing relationship with UW Health and the UW School of Medicine and Public Health. It is the fourth suite of its kind in the world currently being used for patient care, and the first implementation in the world for pediatric interventional radiology. It will be used for research, as well as patient care, Monroe said.

The suite is also expected to double the interventional radiology procedures performed annually at American Family Children’s Hospital, he said.

“When I got here in 2021, we did about 300 interventional radiology procedures per year, and now we’re up to 800,” Monroe said. “But we still saw delays or patients going elsewhere because we didn’t have the space to care for the volume of patients we would have liked to.”

Access to Pediatric Heart Care

This move will increase access to pediatric heart care for UW Health Kids patients by expanding available space in pediatric interventional cardiology, as the interventional radiology team previously shared the space with that team. It will also increase capacity in the operating rooms at the children’s hospital by enabling more care to be delivered in the minimally invasive suite.

“There are many procedures that can be done in interventional radiology or in the operating room,” Monroe said. “Now our surgeons will have more capacity for the patients who need their specific expertise and the operative environment.”

This state-of-the-art suite is also key to attracting the best talent to Madison, according to Monroe.

“We have the best team and want to be sure we’ve also got the best tools that ensure the best people want to come work with us here in Wisconsin,” he said.

Thursday, July 23, 2026 - 12:25

ASTRO Names 2026 Fellows

tim.hodson — Thu, 23 Jul 2026 15:28:23 +0000

tim.hodson Thu, 07/23/2026 - 10:28

July 22, 2026 — The American Society for Radiation Oncology (ASTRO) has announced the 39 members who will receive the ASTRO Fellow (FASTRO) designation this year. This honor recognizes ASTRO members’ outstanding achievements and contributions to the Society, cancer research, education, patient care and the specialty. The new Fellows will be recognized at ASTRO’s 68th Annual Meeting in Boston in September.

The FASTRO designation recognizes sustained achievement and service to ASTRO, the field of radiation oncology and patient care. First awarded in 2006, the designation has been awarded to just 580 of ASTRO’s more than 10,000 members worldwide. The incoming class of Fellows includes physicians, medical physicists and scientists whose work has advanced the science and delivery of radiation therapy for people with cancer and other diseases.

“The 2026 ASTRO Fellows reflect the depth and breadth of leadership in radiation medicine,” said ASTRO CEO Vivek S. Kavadi, MD, MBA, FASTRO. “Their careers demonstrate the many ways ASTRO members move our field forward through discovery, clinical excellence, education, mentorship and service. We are proud to recognize this distinguished class.”

2026 ASTRO Fellows

The 2026 Fellows are:

Michelle Alonso-Basanta, MD, PhD, University of Pennsylvania
Smith Apisarnthanarax, MD, University of Washington/Fred Hutchinson Cancer Center
Richard Bakst, MD, Icahn School of Medicine at Mount Sinai
Christopher Barker, MD, Memorial Sloan Kettering Cancer Center
Carmen Bergom, MD, PhD, Washington University School of Medicine
Melisa Boersma, MD, The University of Kansas Cancer Center/KUMC/TUKHS
Stuart Burri, MD, Southeast Radiation Oncology Group
Jimmy Caudell, MD, PhD, Moffitt Cancer Center
Luqman Dad, MD, MBA, Maryland Oncology Hematology
Parima Daroui, MD, PhD, City of Hope National Medical Center
Issam El Naqa, PhD, Moffitt Cancer Center & Research Institute
Ralph Ermoian, MD, University of Washington
Steven Finkelstein, MD, Associated Medical Professionals (AMP)/USUP
Daphna Gelblum, MD, Memorial Sloan Kettering Cancer Center
Lia Halasz, MD, University of Washington
Matthew Harkenrider, MD, Loyola University Medical Center
Ariel Hirsch, MD, Boston University Chobanian and Avedisian School of Medicine
Krisha Howell, MD, MHP Radiation Oncology Institute
Candice Johnstone, MD, MPH, Medical College of Wisconsin
Mitchell Kamrava, MD, Cedars-Sinai Medical Center
Alexander Louie, MD, PhD, Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto
Michelle Ludwig, MD, PhD, MPH, University of Colorado Anschutz
Danielle Margalit, MD, MPH, Dana-Farber Brigham Cancer Center
David Marshall, MD, Medical University of South Carolina
Malcolm Mattes, MD, Rutgers Cancer Institute
Martha Matuszak, PhD, University of Michigan
Rosalyn Morrell, MD, Beverly Hills Cancer Center
Shannon Offerman, MD, Radiation Oncology Associates, Ltd.
Manisha Palta, MD, Duke University
Chelsea Pinnix, MD, PhD, The University of Texas MD Anderson Cancer Center
Christopher Pope, MD, Radiation Oncology Associates, PA
Kristin Redmond, MD, MPH, Johns Hopkins University
Sheila Rege, MD, Northwest Corporate Consulting LLC
Kilian Salerno, MD, National Cancer Institute, National Institutes of Health
Navesh Sharma, DO, PhD, WellSpan Radiation Oncology
Ke Sheng, PhD, University of California, San Francisco
Terence Sio, MD, Mayo Clinic Arizona
Abraham Wu, MD, Memorial Sloan Kettering Cancer Center
David Yu, MD, PhD, Emory University School of Medicine

Candidates for Fellow designation are nominated by current ASTRO Fellows, undergo rigorous peer review and are approved by ASTRO’s Board of Directors.

More information about the program is available online, including the complete list of ASTRO Fellows.

Thursday, July 23, 2026 - 10:28